Text Size

Free Fatty Acids and Vascular Function in Subjects With Diabetes

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00153179
First received: September 8, 2005
Last updated: August 5, 2011
Last verified: August 2011
History of Changes
  Purpose

This study will test the hypothesis that reduction in release of free fatty acids from adipocytes will restore insulin-mediated endothelium-dependent vasodilation and skeletal muscle glucose metabolism in subject with type 2 diabetes.


Condition Intervention Phase
Type 2 Diabetes Mellitus
 Drug: acipimox
Drug: placebo
 Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Impact of Free Fatty Acid Reduction on Vascular Function and Skeletal Muscle Glucose Utilization in Type 2 Diabetes Mellitus

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • difference in endothelium-dependent vasodilation between test agent and placebo [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • difference in flow-mediated, endothelium-dependent brachial artery vasodilation between test agent and placebo [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • difference in insulin-mediated skeletal muscle glucose utilization between test agent and placebo [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: September 2005
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Drug: acipimox
subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
Other Name: Olbetam
Placebo Comparator: 2
placebo
 Drug: placebo
matching placebo

Detailed Description:

During the past two decades, there has been a steady increase in the incidence of diabetes mellitus, such that nearly 17 million people are now afflicted. The vast majority of these have type 2 diabetes. Over the next 40 years, the type 2 diabetic population in the United States is expected to increase to nearly 30 million.

Diabetes substantially increases the risk of atherosclerosis, and thereby, cardiovascular morbidity and mortality. Indeed, cardiovascular disease causes more than 50% of the mortality in patients with diabetes. People with type 2 diabetes manifest two cardinal signs of dysmetabolism: hyperglycemia and insulin resistance. Insulin resistance is a progressive phenomenon that occurs well before the onset of frank diabetes, and results in alterations in insulin signaling. Experimental studies suggest that insulin signaling is required for vascular homeostasis, and its impairment is associated with endothelial dysfunction. In the clinical setting, insulin resistance is associated with atherosclerosis and predicts cardiovascular events independent of hyperglycemia. Therefore, we will study the importance of insulin signaling in endothelial biology in humans and the effects of free fatty acids on endothelial function in people with type 2 diabetes.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • type 2 diabetes mellitus (as defined by the National Diabetes Data Group)
  • normal cardiovascular exam
  • non smoker (for 1 year prior to entry)
  • Healthy volunteers
  • no known medical problems
  • normal cardiovascular exam
  • fasting glucose < 110 mg/dL
  • non-smoker (for 1 year prior to entry)

Exclusion Criteria:

Type 2 Diabetics

  • untreated hypertension (>140/90 mmHg)
  • untreated hypercholesterolemia (LDL > 75th percentile for age)
  • cigarette smoking within 1 year
  • neuropathy requiring medication
  • nephropathy (> 300mg/24 hour urinary albumin, or serum creatinine > 1.4 mg/dL
  • abnormal cardiovascular exam
  • treatment with thiazolidinedione within 1 year
  • post-menopausal women taking hormone replacement therapy

(Note: subjects taking angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) must stop these medications for 2 weeks prior to taking study drug. If blood pressure rises to >140/90, subjects will be prescribed an alternative medication or be withdrawn from the study.

Healthy Volunteers

  • abnormal cardiovascular exam
  • use of prescription medications
  • fasting glucose > 110mg/dL
  • cigarette smoking within 1 year
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00153179

Locations
United States, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Principal Investigator: Mark Creager, M.D. Brigham and Women's Hospital
  More Information

No publications provided

Responsible Party: Mark A. Creager, M.D., Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT00153179     History of Changes
Other Study ID Numbers: 2005P-000088
Study First Received: September 8, 2005
Last Updated: August 5, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Brigham and Women's Hospital:
insulin resistance
insulin signaling
endothelium-dependent vasodilation

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Acipimox
 Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2013